Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MonoSol Rx, the developer of PharmFilm drug delivery technology, is developing migraine product for treatment of pain and nausea in a single dose.
Subscribe to our email newsletter
The migraine treatment drug candidate, MSRX-202, leverages MonoSol PharmFilm technology in a combination product that includes rizatriptan for the treatment of migraine pain and ondansetron for the treatment of nausea.
MonoSol Rx president and chief executive officer Mark Schobel said that MSRX-202 represents a new approach to migraine treatment that addresses both pain and nausea.
"MSRX-202 fulfills this unmet patient need and additionally has the potential to be the fastest acting oral migraine pain medication on the market," Schobel added.
"Our preclinical and first-in-man pharmacokinetic studies indicate that the therapeutic dose will provide relief from pain in as little as fifteen minutes without the use of a device."
Preclinical and first-in-human pharmacokinetic studies indicate that MSRX-202 will reach therapeutic levels for rizatriptan in as little as fifteen minutes while maintaining the well-known pharmacokinetic profile of ondansetron, according to the company.